Scientists uncover a molecular weakness that could transform prostate cancer therapy. An international team of researchers has identified a new weakness in prostate cancer cells that could enhance ...

GSK said it acquired exclusive worldwide rights for a drug candidate targeting prostate cancer from France's Syndivia for up to 268 million pounds ($356.8 million).

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) ...

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

A globally-renowned prostate cancer surgeon shares the latest advancements in the field and stresses the importance of early ...

Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone.

The 2025 edition of the European Society for Medical Oncology(ESMO) was held this week in Berlin, delve into its key ...

NICE recommendation of darolutamide plus hormone therapy for metastatic prostate cancer offers around 6000 patients in ...

Grape seed extract—a dietary supplement made from the seeds of wine grapes—has been investigated to see if it can help reduce ...